Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Biocytogen Signs Three-Year Antibody Discovery Pact with Gilead Sciences

publication date: Feb 20, 2024

Biocytogen Pharma (Beijing) signed an antibody evaluation/option agreement with Gilead Sciences, granting access to Biocytogen’s fully human antibody library aimed at a wide range of therapeutic targets. Over a three-year period, Gilead will nominate targets of interest and evaluate the corresponding antibodies, with an option to acquire global rights for promising antibodies. Biocytogen will receive a payment to enable Gilead’s evaluation of antibodies for a specific target, and it will be eligible to receive option exercise fees along with milestone payments for each selected antibody, plus single-digit royalties on net sales. Specific details of the agreement were not disclosed. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital